People: Assembly Biosciences Inc (ASMB.OQ)

ASMB.OQ on NASDAQ Stock Exchange Global Select Market

8:58pm IST
Change (% chg)

$-0.81 (-4.89%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Lopatin, Uri 

Dr. Uri Lopatin, M.D. is the Vice President - Research & Development, Chief Medical Officer of tAssembly Biosciences Inc. At Assembly Pharmaceuticals, he was Chief Medical Officer and Vice President Research and Development, a position he held since October, 2012. Prior to that, he was a Senior Director for Clinical and Translational Research-Liver Disease at Gilead Sciences from October, 2010 to September, 2012, a Translational Medical Leader at Roche from May, 2008 to September, 2010. Dr. Lopatin has designed and coordinated pre-clinical and clinical collaborations, as well as phase I through IV clinical studies of multiple new molecular entities. Dr. Lopatin has published extensively, especially on hepatitis B and immunology and is an author of multiple patents in the field of treatment and diagnosis for viral hepatitis. Dr. Lopatin received his infectious disease Board certification following fellowship training in ID at the NIH, and internal medicine board certification following completion of residency at NYU. Dr. Lopatin received his MD in 2000 from University of Medicine and Dentistry-New Jersey Medical School, where he was awarded the Stanley S. Bergen medal of excellence.

Basic Compensation

Total Annual Compensation, USD 504,052
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 224,342
Fiscal Year Total, USD 728,394

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --